HOW BEING SICK AND KEEPING YOU SICK LEADS TO BIG PROFITS IN THE HEALTHCARE SECTOR BY AOP3D

---

The Economic Paradox of American Healthcare: Maintenance over Cure

 

The United States healthcare apparatus operates on a distinct economic paradox: the financial solvency of its major institutions—hospital systems, pharmaceutical manufacturers, and insurance conglomerates—is often inversely correlated with the curative outcomes of the patient population.

While the stated mission of medical care is the eradication of disease, the operational business model has shifted decisively toward the management of chronic conditions, a model that transforms patients into perpetual revenue streams.

 

 

This report provides an exhaustive examination of the structural incentives that prioritize "maintenance" over "cure," utilizing the specific clinical trajectory of cancer survivorship and iatrogenic (treatment-induced) disability as a primary case study.

 By dissecting the micro-economics of specific billing codes, pharmaceutical patent gaming, and regulatory arbitrage, we expose a system where financial toxicity is a central design feature.

 

 

---

Part I: The "Goldman Sachs Question" and the Macro-Economics of Disease

 

 

1.1 The Genome Revolution and the Sustainability of Cures

In April 2018, Goldman Sachs analysts released a report titled The Genome Revolution. It posed a chilling question for investors: "Is curing patients a sustainable business model?"

 

 

Analyst Salveen Richter identified a fundamental structural risk in gene therapy: the potential to deliver "one-shot cures." While attractive to patients, these treatments offer a poor outlook for recurring revenue compared to chronic therapies.

 

 

1.1.1 The Gilead Paradox: Punishment for Success

 

 

Gilead Sciences’ Hepatitis C drugs (Sovaldi and Harvoni) offered cure rates exceeding 90%.

 

 

• Public Health Result: A triumph; the "incident pool" (new infections) collapsed.

• Financial Result: A disaster for shareholders. Sales plummeted from $12.5 billion in 2015 to less than $4 billion in subsequent years.

 

The market effectively punished the company for being too effective.

1.2 The "Incident Pool" as a Strategic Asset

The industry distinguishes between two types of patient groups:

• The Cure Model: Focuses on reducing prevalence. Success eventually eliminates the market.

• The Maintenance Model: Focuses on managing prevalence. It keeps patients "stable" and paying, ensuring a steady stream of revenue.

---

Part II: The Business of Survivorship

 

 

A Case Study in Manufactured Disability

 

 

When a patient survives cancer, they often transition from an "acute care" profit center to a "chronic management" profit center.

 

 

2.1 Cisplatin: The Mechanism of Ototoxicity

 

 

Cisplatin is a highly effective chemotherapy agent, but it is a blunt instrument. It accumulates in the cochlea, destroying hair cells essential for hearing.

 

 

• Pediatric Patients: 40% to 60% suffer permanent hearing loss.

• Adult Patients: Estimates range up to 36% or higher.

• Economic Impact: The socioeconomic cost of this hearing loss is estimated at over $350,000 per person.

 

2.2 The "Missing Cure" for Hearing Loss

 

 

Sodium Thiosulfate (STS) can neutralize cisplatin before it destroys the inner ear. However, the FDA-approved version (Pedmark) is indicated only for pediatric patients.

 

 

• Pedmark Price: Approximately $11,160 per vial.

• Generic Price: Pennies, but its use is discouraged by regulatory warnings.

 

The result? Adults are often administered the "poison," allowed to go deaf, and then billed for a lifetime of audiology services and hearing aids.

 

 

---

Part III: The Micro-Economics of the Ear Canal

Deep Dive into CPT 69210

The frustration of being billed every 3 months for ear wax removal (cerumen impaction) highlights the "fee-for-sickness" model.

 

 

Location	Procedure	Cost to Patient
UK (Private)	Microsuction	~$75 (Fixed price)
US (Self-Pay)	CPT 69210	$100 – $250
US (Hospital Outpatient)	CPT 69210 + Facility Fee	$300 – $700+

The 90-Day Cycle: Medicare and insurers often only reimburse for this procedure every 60 to 90 days. This forces a cycle where a patient must wait until they are "symptomatic" (suffering) to justify the medical necessity of the billable event.

 

 

---

Part IV: The "Facility Fee" Racket

 

A significant portion of medical inflation stems from Facility Fees. When a hospital acquires a private practice, they begin charging a "Professional Fee" (for the doctor) and a "Facility Fee" (for the building).

 

 

• The Telehealth Absurdity: In 2024, cases emerged of hospitals charging facility fees for Zoom calls where the patient and doctor were both at home.

• Lobbying: The American Hospital Association spends millions to block "Site-Neutral" payments, which would require the same price for a service regardless of whether it happens in a hospital or an office.

 

---

Part V: The "Non-Profit" Facade

 

 

Most US hospitals are 501(c)(3) "non-profits." However, this status often hides massive executive wealth transfers.

 

 

• The Pay Gap: Between 2009 and 2023, non-profit hospital CEO compensation rose by 27.5%, while worker wages rose by only 9.8%.

• The Incentive: CEO pay is correlated with hospital volume and revenue, not patient health.

 

---

Conclusion: The Economics of the Hamster Wheel

 

 

The healthcare industry does not necessarily desire human suffering, but it does desire billable events.

 

 

• For Pharma: A cured patient is a lost customer.

• For Hospitals: A healthy person is worth $0; a person in an outpatient department is worth $500.

 

The system is not broken; it is working exactly as its incentives were designed. It is a machine that converts human biology into executive compensation, with the patient serving as both the fuel and the exhaust.

 

 

 

---

Data Summary: The "Profit from Sickness" Matrix

Incentive Structure	Cure / Prevention Model	Chronic / Maintenance Model
Pharma Revenue	One-time payment (High Risk)	Recurring annuity (Low Risk)
Hospital Revenue	Minimizes visits (Low Volume)	Maximizes visits (High Volume)
Patient Outcome	Health restoration	Financial toxicity

---